TY - JOUR
T1 - Access to therapy in the multicenter AIDS Cohort Study, 1989-1992
AU - Graham, Neil M.H.
AU - Jacobson, Lisa P.
AU - Kuo, Victor
AU - Chmiel, Joan S.
AU - Morgenstern, Hal
AU - Zucconi, Sharon L.
N1 - Funding Information:
Acknowledgements-This study was supported by NIH cooperative agreements UOI-AI-35039, -35040, -35041, -35042, -35043 and supplemental support through an interagency agreement with the Agency for Health Care Policy and Research (AHCPR). The authors would like to thank Dr Peter Arno for his helpful comments on this manuscript and MS Harriet Grossman for helping with its preparation. The investigators in the Multicenter AIDS Cohort Study are: Baltimore: The Johns Hopkins Universitv School of Hygiene and Public Health: A: J. Saah, Princjpal Investigator; J. Palenicek, H. Armenian, H. Farzadegan, N. M. H. Graham, J. Margolick, J. McArthur. Chicago: Howard Brown Health Center and Northwestern University Medical School: J. P. Phair, Principal Investigator; J. S. Chmiel, B. Cohen. M. G’Gorman. D. Variakoiis. J. Wesch, S. Wolinsky. Los Angeles: University of Cahfornia, UCLA Schools of Public Health and Medicine: R. Detels, Principal Investigator; B. Visscher, I. Chen, J. Dudley, J. Fahey, J. Giorgi, Moon Lee, 0. Martinez-Maza, E. Miller, H. Morgenstern, P. Nishanian, J. Taylor, J. Zack. Pittsburgh: Universitv of Pittsburgh Graduate School of Public Health: C. kinaldo, Jr, Principal Investigator; L. Kingsley, J. Becker, P. Gupta, Monto Ho., S. L., Zucconi; Data Coordinating Center (CAMACS): The Johns Hopkins School of Hygiene and Public Health: A. Munoz, Principal Investigator; T. Beaty, L. Epstein, N. Galai, D. Hoover, L. P. Jacobson, V. Kuo, C. Meinert, K. Nelson, S. Piantadosi, Sol Su. NIH: National Institute of Allergy and Infectious Diseases: L. Schrager, Project Officer; S. Vermund, R. Kaslow, M. VanRaden. National Cancer Institute: D. Seminara.
PY - 1994/9
Y1 - 1994/9
N2 - The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95 % CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).
AB - The study aims were (i) to describe secular trends in the utilization of antiretrovirals, antivirals, Pneumocystis carinii pneumonia (PCP) prophylaxis, and antifungal prophylaxis and (ii) to determine whether factors such as clinical status, health services utilization, insurance status, income, education and race were associated with access to therapy. Data on utilization of therapy, health services utilization, income and insurance status were collected semiannually from October 1990 through March 1992 from 1415 homosexual/bisexual HIV-1 seropositive men in the Multicenter AIDS Cohort Study (MACS). Prevalence of therapy use according to level of immunosuppression was determined at each study visit. Clinical AIDS was defined using the 1987 CDC definition. Factors associated with use of antiretroviral therapy and PCP prophylaxis were assessed using multiple logistic regression with robust variance techniques to adjust variance estimates and significance levels for within-person correlations of drug use over time. Prevalence of zidovudine use remained relatively constant throughout the study period. In contrast, use of didanosine (21-34%), acyclovir (23-34%) and dideoxycytidine (zalcitabine) (8-25%) increased in participants with clinical AIDS. Similar trends were seen for combination antiretroviral therapy, trimethoprim-sulfamethoxazole, dapsone, ketoconazole and fluconazole. However, reported use of aerosolized pentamidine fell. After adjusting for CD4+ lymphocyte count and HIV-1 symptoms, previous HIV-related hospitalization (OR = 1.52; 95% CI = 1.22-1.91), outpatient visit (OR = 2.83; 95% CI = 2.12-3.78), having insurance (OR = 1.32; 95% CI = 1.01-1.75), college education (OR = 1.42; 95 % CI = 1.13-1.80) and white race (OR = 1.58; 95% CI = 1.21-2.07) were all associated with being on antiretroviral therapy in persons without clinical AIDS. In persons with clinical AIDS, having insurance (OR = 2.89; 95% CI = 1.04-8.02) and a previous outpatient visit (OR = 11.69; 95% CI = 1.77-77.30) were the significant variables. Factors significantly associated with being on PCP prophylaxis in multivariate models were previous hospitalization, previous outpatient visit, and college education (for subjects without clinical AIDS).
KW - AIDS
KW - Didanosine
KW - Dideoxycytidine
KW - HIV-1
KW - Health care utilization
KW - Zidovudine
UR - http://www.scopus.com/inward/record.url?scp=0028088166&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028088166&partnerID=8YFLogxK
U2 - 10.1016/0895-4356(94)90115-5
DO - 10.1016/0895-4356(94)90115-5
M3 - Article
C2 - 7730902
AN - SCOPUS:0028088166
SN - 0895-4356
VL - 47
SP - 1003
EP - 1012
JO - Journal of Chronic Diseases
JF - Journal of Chronic Diseases
IS - 9
ER -